Instructions for Femoston Conty 5/1 (Estradiol, Dydrogesterone) 28 pills
English product name
Femoston® conti
Release form
Coated tablets
Description:
Tablets covered with film sheath in orange-pink, round, double-convex, with engraving "379" on one side; view of tablets on a cross section: white, rough surface.
1 tab.
estradiol hemihydrate 1.03 mg,
which corresponds to estradiol content 1 mg
didrogesteron 5 mg
Auxiliary substances: lactose monohydrate - 114.7 mg, hypromellose (HPMC 2910) - 2.8 mg, corn starch - 14.4 mg, silicon dioxide colloidal - 1.4 mg, magnesium stearate - 0.7 mg.
Film sheath composition:
Orange I* film coating compound (hypromellose (HPMC 2910) - 71.092%, macrogol 400 - 7.108%, titanium dioxide (E171) - 20%, iron oxide yellow (E172) - 1.2%, iron oxide red (E172) - 0.6%) - 4 mg.
ATC Codes
G03FA14 Dydrogesterone and Estrogen
Clinical and pharmacological groups / Group affiliation
Antimenopausal drug
Active ingredient
dydrogesterone
Estradiol
Pharmaco-therapeutic group
Antimenopausal agent combined (estrogen + gestagen)
Storage conditions Femoston
The drug should be stored out of the reach of children at a temperature not exceeding 30 ° C.
Shelf life
Shelf life - 3 years. Do not use after the expiration date.
Testimony Femoston:
- hormone replacement therapy for disorders caused by estrogen deficiency in postmenopausal women (no earlier than 12
- months after the last menstruation);
- prevention of postmenopausal osteoporosis in women with a high risk of fractures with intolerance or contraindications to
- the use of other drugs.
Method of use, course and dosage:
The drug is taken daily for 28 days, in continuous mode one tablet per day (preferably at the same time of day), regardless of the meal.
The treatment should continue without interruption, immediately after the end of the twenty-eight day cycle, the next treatment cycle should be started.
For the initiation and continuation of GST treatment of estrogen deficiency disorders, the combination of didrogesteron and estradiol should be used at the lowest effective dose and for the shortest period of time. Depending on the clinical response, the dose can be adjusted later.
When switching from another continuous sequential or cyclic mode of the drug intake, it is necessary to finish the current cycle, and then go to the drug Femoston® conti.
For women who have not previously received a DHT or who have switched from another continuous combined DHT regimen, Femoston® should be taken any day.
If the patient has missed the next dose, the pill must be taken within twelve hours of the usual intake time. If more than twelve hours have passed, the tablet should not be taken, the next day you should take the tablet at normal time. Skipping the drug can increase the likelihood of "breakthrough" uterine bleeding or "smearing" blood secretions.
Use in renal dysfunction
With caution should be used in renal failure.
Use in case of impaired liver function Femoston
Contraindicated in acute or chronic liver diseases at present or in the anamnesis (until the normalization of laboratory indicators of liver function), incl. malignant tumors of the liver.
Terms of implementation
The drug is dispensed by prescription.
Use in elderly patients
The experience of using the drug in women over 65 years of age is limited.
- Nosology (ICD codes)
- M80.0
- Postmenopausal osteoporosis with pathological fracture
- M80.1
- Osteoporosis with pathological fracture after removal of the ovaries
- M81.0
- Postmenopausal osteoporosis
- M81.1
- Osteoporosis after ovarian removal
- N95.1
- Menopause and menopause in women
- N95.3
- Conditions associated with artificially induced menopause
Pharmacological action:
Estradiol, which is part of the drug Femoston® conti, is identical to human endogenous estradiol, which is the most active estrogen.
Estradiol replenishes the deficiency of estrogens in the female body in women at menopausal age and reduces menopausal symptoms during the first weeks of treatment.
Hormone replacement therapy (HRT) with Femoston® conti prevents bone loss in the postmenopausal period or after ovarioectomy.
Dydrogesterone is a progestogen that is effective when taken orally and has activity similar to parenterally administered progesterone.
